Allscripts Healthcare Stock
Allscripts Healthcare Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Allscripts Healthcare stock is not clear.
As a result the target price of 10 € shows a positive potential of 38.89% compared to the current price of 7.2 € for Allscripts Healthcare.
Pros and Cons of Allscripts Healthcare in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allscripts Healthcare vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Allscripts Healthcare | - | 0.000% | -2.703% | -34.545% | -22.162% | -47.826% | -22.128% |
MicroVision Inc | 2.990% | -19.622% | -21.413% | -69.607% | -58.963% | -90.885% | 50.203% |
Fonar Corp. New | -5.040% | -12.000% | -14.839% | -15.385% | -25.424% | -12.583% | -30.577% |
Fluidigm Corp. | -1.720% | 1.786% | 0.000% | 12.871% | 10.680% | -50.809% | - |
Comments
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at Royal Bank of Canada from $22.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat